Medical Condition News

RSS

Promising new therapeutic strategy for chronic kidney disease

Chronic kidney disease (CKD) affects at least one in four Americans who are older than 60 and can significantly shorten lifespan. Yet the few available drugs for CKD can only modestly delay the disease's progress towards kidney failure. Now, however, a team led by researchers at the Perelman School of Medicine at the University of Pennsylvania, has found an aspect of CKD's development that points to a promising new therapeutic strategy.

1 Dec 2014

Obstructive sleep apnea associated with impaired exercise capacity

A new study shows that obstructive sleep apnea is associated with impaired exercise capacity, which is an indicator of increased cardiovascular risk.

1 Dec 2014

Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A

Nektar Therapeutics reported that partner Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) to the United States Food and Drug Administration for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].

From Baxter International Inc. 1 Dec 2014

Philips introduces new lung screening solution at RSNA 2014

Royal Philips today introduced a new lung screening solution designed to offer health care providers a faster and more definitive pathway to lung cancer detection and treatment. Making its debut at the 2014 Radiological Society of North America Annual Meeting in Chicago this week, this total solution is comprised of products and services that enable health care providers to implement and manage a comprehensive computed tomography (CT) lung screening program which tracks and guides patients across the health continuum.

1 Dec 2014

Eylea receives Health Canada approval for treatment of CRVO and DME

Bayer Inc. announced today that it has received approval from Health Canada for Eylea (aflibercept, solution for intravitreal injection) for the treatment of diabetic macular edema (DME). This new indication comes just six weeks following the October 16th approval of Eylea for the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO).

1 Dec 2014

Clementia's palovarotene receives FDA Fast Track designation for FOP treatment

Clementia Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to palovarotene, which is being developed for the treatment of fibrodysplasia ossificans progressiva (FOP).

1 Dec 2014

Eli Lilly, AstraZeneca begin AZD3293 Phase II/III study for treatment of early Alzheimer's disease

Eli Lilly and Company and AstraZeneca today announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease.

1 Dec 2014

Different forms of ASIC1a gene associated with panic disorder

Panic disorder is a severe form of anxiety in which the affected individual feels an abrupt onset of fear, often accompanied by profound physical symptoms of discomfort.

1 Dec 2014

Griffith University student explores impact of computer games on older adults

Griffith University PhD student, Milton Nyawata, is looking for people over the age of 60 to take part in a study into the effects of computer games on older Australians.

1 Dec 2014

Researchers identify new genetic biomarkers that predict outcomes for patients with bowel cancer

Researchers at University of Limerick and University Hospital Limerick have identified several new genetic biomarkers which better predict outcomes for patients with bowel/colorectal cancer. The research team identified genes that are predictors of cancer recurrence and can also help to identify a patients’ suitability to specific types of chemotherapy.

1 Dec 2014

Bilingualism has protective effect in delaying Alzheimer's disease symptoms

A new study at Ghent University has established that the symptoms of Alzheimer disease (AD) manifest themselves about four to five years later in bilinguals as opposed to monolinguals. In bilinguals, the disease onset was estimated at the age of 77, while in monolinguals, this was at the age of 73.

1 Dec 2014

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

Pharmacyclics, Inc.today announced the acceptance of a Type II variation application for IMBRUVICA (ibrutinib) by the European Medicines Agency.

1 Dec 2014

CTI BioPharma announces upcoming presentations of pacritinib data at ASH Annual Meeting

CTI BioPharma Corp. (CTI) today announced the upcoming presentations of data highlighting pacritinib, an oral multikinase inhibitor with dual activity against JAK2 and FLT3, and tosedostat, an oral selective inhibitor of aminopeptidases, at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6-9 in San Francisco, CA.

1 Dec 2014

DTI may play role in assessing brain damage in early Alzheimer's disease

Changes in brain connections visible on MRI could represent an imaging biomarker of Alzheimer's disease, according to a new study presented today at the annual meeting of the Radiological Society of North America (RSNA).

1 Dec 2014

PET/CT may improve differentiation of PTSD from MTBI

Hybrid imaging with positron emission tomography and computed tomography (PET/CT) in the pituitary region of the brain is a promising tool for differentiating military veterans with post-traumatic stress disorder (PTSD) from those with mild traumatic brain injury (MTBI), according to a new study presented at the annual meeting of the Radiological Society of North America (RSNA).

1 Dec 2014

Brain changes seen in high school football players after one season

Some high school football players exhibit measurable brain changes after a single season of play even in the absence of concussion, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

1 Dec 2014

New active substance effectively combats Philadelphia chromosome-positive leukaemia

Haematologists from Goethe University Frankfurt, working with a Russian pharmaceutical company, have developed a new active substance that effectively combats the most aggressive forms of Philadelphia chromosome-positive leukaemia.

29 Nov 2014

Drinking 3-5 cups of coffee per day may protect against Alzheimer’s Disease

Drinking 3-5 cups of coffee per day may help to protect against Alzheimer’s Disease, according to research highlighted in an Alzheimer Europe session report published by the Institute for Scientific Information on Coffee, a not-for-profit organisation devoted to the study and disclosure of science related to coffee and health.

29 Nov 2014

EMAHSN extends IPS scheme to support people with mental health illness

The 8 December will see the first step in an East Midlands wide approach to supporting people with mental health illness back in to work or education. The East Midlands Academic Health Science Network is championing and extending a widely proven scheme called Individual Placement and Support (IPS) across the region.

28 Nov 2014

Better Care for People with Bipolar Disorder: A new booklet to be launched in December 2014

Bipolar Disorder is in the top 20 causes of years lost due to illness in the world among all health conditions. It affects 1.4% of the population and lasts for the rest of the person’s life. People diagnosed with Bipolar Disorder are 20 times more likely than the general public to commit suicide. In 2007 service provision costs for Bipolar Disorder and related conditions were estimated to be £1.6 billion. This is projected to increase to £2.6 billion by 2026.

28 Nov 2014